

Am J Hematol 2008 Jul;83(7):603-4

PMID: 18273905 DOI: 10.1002/ajh.21116

A new TMHA-DHPLC assay for the rapid mutation screening of JAK2 exon 14 in myeloproliferative disorders

Elena Albiero, Martina Bernardi, Domenico Madeo, Marco Ruggeri, Francesco Rodeghiero

Refractory idiopathic pure red cell aplasia complicated by immune thrombocytopenia successfully treated with subcutaneous alemtuzumab.

To the Editor: Only rare case reports of patients with pure red cell aplasia (PRCA) responding to alemtuzumab exist; however, most are secondary PRCA with only one being idiopathic [1]. We report a man with refractory idiopathic PRCA complicated by ITP, successfully treated with subcutaneous alemtuzumab.

Link all'articolo: <https://pubmed.ncbi.nlm.nih.gov/18273905/>